LONDON (Alliance News) - Motif Bio PLC on Wednesday said the first patient has been dosed in its Iclaprim phase three trials for the treatment of skin infections.
The biopharmaceutical company said the trial will assess the efficacy and safety of Iclaprim in treating acute bacterial skin and skin structure infections, with a total of 1,200 patients to be assessed.
"This is an important milestone for Motif that keeps us on track to complete the trials in the second half 2017. Iclaprim has the potential to be a major addition to the armamentarium of antibiotics much needed for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria in hospitalised patients," said Graham Lumsden, Motif Bio's chief executive.
Motif Bio shares were up 4.4% to 46.45 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
